In Vivo Angiography Quantifies Oxygen-Induced Retinopathy Vascular Recovery.
OBJECTIVE
Retinopathy of prematurity (ROP) is a potentially blinding vasoproliferative disease. There is no standardized way to quantify plus disease (tortuous and dilated retinal vessels) or characterize abnormal recovery during ROP monitoring. This study objectively studies vascular features in live mice during development using noninvasive retinal imaging.


METHODS
Using fluorescein angiography (FA), retinal vascular features were quantified in live mice with oxygen induced retinopathy (OIR). A total of 105 wild-type mice were exposed to 77% oxygen from postnatal day 7 (P7) till P12 (OIR mice). Also, 105 age-matched pups were raised in room air (RA mice). In vivo FA was performed at early (P16 to P20), mid (P23 to P27), late (P30 to P34), and mature (P47) phases of retinal vascular development. Retinal vascular area, retinal vein width, and retinal artery tortuosity were quantified.


RESULTS
Retinal artery tortuosity was higher in OIR than RA mice at early (p < 0.0001), mid (p < 0.0001), late (p < 0.0001), and mature (p < 0.0001) phases. Retinal vascular area in OIR mice increased from early to mid-phase (p < 0.0001), but remained unchanged from mid to late (p = 0.23), and from late to mature phase (p = 0.98). Retinal vein width was larger in OIR mice compared to RA mice during early phase only. Arteries in OIR mice were more tortuous from early to mid-phase (p < 0.0001), but tortuosity remained stable from mid through mature phase. RA mice had an increase in retinal vascular area from early to late phase, but maintained uniform retinal vein width and retinal artery tortuosity in all phases.


CONCLUSIONS
In vivo FA distinguished arterial and venous features, similar to plus disease, and revealed aberrant recovery of OIR mice (arterial tortuosity, reduced capillary density, and absent neovascular buds) that persisted into adulthood. Retinal artery tortuosity may be a reliable, objective marker of severity of ROP. Infants with abnormal retinal vascular recovery may need extended monitoring.
*MD, ODDepartment of Pediatrics and Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Olachi J
OJ
Mezu-Ndubuisi
Arch Ophthalmol. 2000 May;118(5):645-9
10815156
Surv Ophthalmol. 2009 Nov-Dec;54(6):663-70
19665743
Exp Eye Res. 2014 May;122:119-22
24703909
Trans Am Ophthalmol Soc. 2004;102:233-48; discussion 248-50
15747762
Arch Ophthalmol. 2005 Mar;123(3):311-8
15767472
Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2813-26
20484600
Acta Paediatr Suppl. 1954;43(100):131-48
13228020
Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11
7507904
PLoS One. 2014 Nov 03;9(11):e111330
25365578
Arch Dis Child Fetal Neonatal Ed. 2015 Mar;100(2):F179-84
25336678
J Vis Exp. 2014 Jun 23;(88):e51351
24998265
Invest Ophthalmol Vis Sci. 2013 Aug 07;54(8):5294-302
23833070
Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1205-11
19526246
J Comp Neurol. 2007 Oct 1;504(4):404-17
17663451
Invest Ophthalmol Vis Sci. 2014 Mar 28;55(3):1884-92
24550366
Invest Ophthalmol Vis Sci. 2002 Feb;43(2):496-502
11818396
Mol Vis. 2007 Jun 12;13:840-53
17615545
Pediatrics. 2013 Jan;131(1):189-95
23277315
Mol Vis. 2011;17:1577-87
21738387
N Engl J Med. 2011 Feb 17;364(7):603-15
21323540
Doc Ophthalmol. 1995-1996;91(2):87-100
8813488
J Matern Fetal Neonatal Med. 2012 Oct;25 Suppl 3:53-6
23016619
Invest Ophthalmol Vis Sci. 2014 May 27;55(7):4276-87
24867581
JAMA Ophthalmol. 2013 Aug;131(8):1026-32
23702696
Arch Ophthalmol. 2006 Nov;124(11):1669-70
17102031
PLoS One. 2012;7(2):e32167
22348151
Development. 2009 Mar;136(5):833-41
19176586
Ophthalmology. 2015 Jan;122(1):200-10
25444347
Early Hum Dev. 2008 Feb;84(2):77-82
18234457
Ophthalmology. 2009 Jul;116(7):1377-82
19481811
Invest Ophthalmol Vis Sci. 2013 Oct 23;54(10):6968-72
24052641
Biol Neonate. 2005;88(3):237-44
16210846
Doc Ophthalmol. 2011 Feb;122(1):19-27
21046193